cAMPfield's $180M Bet: A Safer Pill for Inflammatory Bowel Disease

SAN DIEGO, CA – June 18, 2026 – In a move that signals a seismic shift in the battle against chronic inflammatory disease, a new biopharmaceutical contender, cAMPfield Therapeutics, has emerged from stealth with a staggering $180 million Series A financing. The company's mission is laser-focused: to advance prifemilast, a potentially best-in-class oral therapy, and fundamentally disrupt the treatment paradigm for millions suffering from inflammatory bowel disease (IBD).

This isn't a typical startup story. The nine-figure investment, led by Frazier Life Sciences and a syndicate of biotech's most discerning financiers, is a resounding vote of confidence not just in a molecule, but in a meticulously crafted strategy. cAMPfield represents the convergence of three powerful forces: a seasoned leadership team with a hall-of-fame track record, a scientifically de-risked asset poised to solve a known problem, and a vast, underserved patient population yearning for a better option. It’s a textbook case of how modern biopharma seeks to build lasting competitive advantage—by assembling the perfect team to unlock the latent value of a promising drug.

The Billion-Dollar Bet on a Better Pill

The sheer scale of the $180 million Series A immediately commands attention, but the real story lies in the 'who' and 'how' behind the capital. cAMPfield was conceived by Mountainfield Venture Partners, a firm specializing in building companies around promising, development-stage assets. This model mitigates early discovery risk, instead focusing capital and expertise on clinical execution.

The team assembled to execute this vision is nothing short of a biotech 'dream team.' The company's founders include executives who were instrumental in the development and commercialization of some of the most successful immunology and IBD drugs in history, including Humira®, Entyvio®, Otezla®, and Zeposia®. This pedigree is the corporate equivalent of a championship-winning roster. These are the minds that have navigated the complex clinical and regulatory pathways, and built the commercial engines, for therapies that generate billions in annual revenue. Their involvement signals to investors that the strategic playbook for prifemilast is already in seasoned hands.

Leading the charge as CEO is Bill Gerhart, a serial entrepreneur and Senior Advisor at Mountainfield with a formidable reputation for creating value. Gerhart has a proven history of building and leading biotech companies to successful exits, developing innovative therapies, and delivering substantial returns to investors. This combination of deep domain expertise from the founders and battle-tested corporate leadership from Gerhart creates a powerful force multiplier.

The asset itself, prifemilast, has a strategic history that further de-risks the venture. Originally developed by vTv Therapeutics and later licensed to China's Newsoara Biopharma, the drug has already been tested in over 700 clinical trial participants. This extensive existing data package, which includes a successful Phase 3 trial for plaque psoriasis, provides a crucial foundation of safety and efficacy information, allowing cAMPfield to bypass years of early-stage work and move directly into global Phase 2 trials for ulcerative colitis and Crohn's disease.

The Science of Selectivity: Targeting a Known Problem

At the heart of cAMPfield's strategy is a nuanced scientific advantage. Prifemilast belongs to a class of drugs known as phosphodiesterase 4 (PDE4) inhibitors. This class is already validated, with drugs like Amgen's Otezla (apremilast) proving that inhibiting PDE4 can effectively treat inflammatory conditions. However, the first generation of these drugs has been hampered by a significant Achilles' heel: tolerability.

Many patients taking older, non-selective PDE4 inhibitors experience dose-limiting gastrointestinal side effects like nausea and diarrhea. This is believed to be caused by the inhibition of the PDE4D subtype. The scientific innovation behind prifemilast is its selectivity. The drug is designed to preferentially inhibit PDE4B, the subtype most strongly associated with the desired anti-inflammatory effects, while having less impact on PDE4D. In theory, this precision targeting could deliver the therapeutic benefits of the drug class without the burdensome side effects that lead many patients to discontinue treatment.

This 'best-in-class' potential is what makes prifemilast so compelling. The extensive clinical history has already shown treatment discontinuation rates comparable to placebo, a remarkable finding for this drug class. If the upcoming IBD trials can demonstrate robust efficacy alongside this superior tolerability, prifemilast could offer a combination of benefits that currently eludes the market: the power of a biologic with the convenience and safety of a truly next-generation oral therapy.

Redefining 'Normal' for Millions with IBD

For the more than 2.4 million people in the United States living with IBD, the launch of cAMPfield is more than just a business transaction; it's a beacon of hope. Life with Crohn's disease or ulcerative colitis is often a relentless cycle of painful flares, debilitating symptoms, and a frustrating search for a treatment that works without intolerable side effects. While injectable biologics have transformed care for many, they require infusions or self-injections that can be burdensome and inconvenient. Existing oral options, meanwhile, often force a trade-off between efficacy, safety, and tolerability.

cAMPfield aims to shatter this paradigm. The company's vision is to establish a new standard of care where patients no longer have to make these compromises. As CEO Bill Gerhart stated, "Despite the availability of more than a dozen approved therapies for IBD, most patients fail to achieve deep and durable remission, while others discontinue or switch treatments because of limitations in safety or long-term effectiveness."

Gerhart's confidence is rooted in the convergence of factors his company now commands. "Supported by the clinical validation of PDE4 inhibition, the best-in-class potential of prifemilast, and our team's deep experience in IBD drug development, we aim to establish prifemilast as the treatment of choice for patients and physicians seeking robust disease control with a convenient once-daily, well-tolerated oral therapy," he added.

The initiation of global Phase 2b trials in moderate-to-severe ulcerative colitis and a Phase 2 trial in Crohn's disease marks the first major step in this ambitious journey. The results of these studies will be scrutinized by the entire industry, as they will provide the first definitive proof of whether prifemilast can deliver on its immense promise. For investors, it’s a calculated bet on a massive market. For the team at cAMPfield, it's the execution of a well-defined strategy. But for millions of patients, it represents the potential for a simpler, safer, and more effective way to manage their chronic disease.